SAN DIEGO (AP) _ Neurocrine Biosciences Inc. (NBIX) on Tuesday reported fourth-quarter profit of $34 million.
On a per-share basis, the San Diego-based company said it had profit of 35 cents.
The results fell short of Wall Street expectations. The average estimate of 10 analysts surveyed by Zacks Investment Research was for earnings of 82 cents per share.
The biopharmaceutical company posted revenue of $244.1 million in the period, exceeding Street forecasts. Four analysts surveyed by Zacks expected $242.4 million.
For the year, the company reported profit of $37 million, or 39 cents per share. Revenue was reported as $788.1 million.
Neurocrine shares have dropped 4% since the beginning of the year. In the final minutes of trading on Tuesday, shares hit $103.10, a climb of 17% in the last 12 months.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on NBIX at https://www.zacks.com/ap/NBIX
Automated Insights, source Associated Press News